Fig. 2
From: Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue
Reproducibility of the FAIMS-PRM assay for RASG12C and wild-type RAS from FFPE clinical samples. (A) Consecutive tumor sections, (B) Adjacent tumor areas. Tumors T1-T4 are known to have the KRASG12C mutation and Tumors T5-T7 are wild-type KRAS. The LLOQ for both RASG12C and wild-type RAS are 46 amol/µg, as shown by the dashed line. The %CVs for each measurement are provided above each boxplot for samples with concentrations above the LLOQ, otherwise shown as not applicable (NA)